Trial · NCT07337447
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival (%) between FOLFIRI and FOLFIRI+Zimberelimab+Domvanalimab | 6 months after the start of treatment 12 months after the start of treatment | Length of time from randomization that patients included in the study are still alive. Analyzed in modified intention to treat |
| Secondary | Progression free survival (PFS) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | Time from randomization to disease progression or death, whatever the cause. Alive and no progressive patients at last follow-up will be considered as censored |
| Secondary | Overall response rate (ORR) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | local radiological evaluation using RECIST 1.1 |
| Secondary | Duration of response (DoR) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | Time from response (complete or partial) to progression or death, estimated in patients who reached a response and are RECIST 1.1 evaluable |
| Secondary | Disease control rate | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | Defined as the proportion of RECIST 1.1 evaluable patients in objective response or with stable disease. |
| Secondary | Evaluation of toxicity | At the Day 1 of each cycles (each cycle is 4 weeks) | assessed by NCI CTCAsE v5.0 |
| Secondary | Evaluation of toxicity | at the Day 15 of each cycles (each cycle is 4 weeks) | assessed by NCI CTCAsE v5.0 |
| Secondary | Questionnaire Quality of life QLQ-C30 | at the day 1 of Cycle 2 (1 cycle is 4 weeks) | Questionnaire QLQ-C30 |
| Secondary | Questionnaire Quality of life EQ 5D-5L | at the day 1 of Cycle 2 (1 cycle is 4 weeks) | Questionnaire EQ 5D-5L |
| Secondary | Questionnaire Quality of life | Every 8 weeks through study completion, an average of 2 years | Questionnaire QLQ-C30 |
| Secondary | Questionnaire Quality of life | Every 8 weeks through study completion, an average of 2 years | Questionnaire EQ 5D-5L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07337447/registered